What development phase is CARBARIL in?

CARBARIL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CARBARIL

FDA-approved withdrawn Small molecule Quality 2/100

CARBARIL is a marketed drug with a key composition patent expiring in 2028, positioning it as a well-established product in its therapeutic category. Its primary strength lies in its current market presence, leveraging the protection of its key patent to maintain revenue streams. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	CARBARIL
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CARBARIL CI brief — competitive landscape report
CARBARIL updates RSS · CI watch RSS